ODTX
Odyssey Therapeutics, Inc.
$16.69
-0.14 (-0.83%)
At close · Jul 10
Going-concern doubt
— cleared Jun 17, 2026
The latest filing states the doubt was alleviated.
“Upon closing of the IPO and concurrent private placement, and receipt of the associated cash proceeds, the Company believes the conditions that raised substantial doubt have been resolved. The Company believes that its existing cash, cash equivalents and marketable securities of $175.7 million as of March 31, 2026, together with the additional net proceeds of $288.7 million received from the IPO, concurrent private placement and the underwriters' exercise of the option to purchase additional shares of common stock, will be sufficient to allow the Company to fund operations at least twelve months from the date that the condensed consolidated financial statements are issued.”View the 10-Q filed Jun 17, 2026
Market Cap
$754.09M
Shares
48,031,320
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.69
Open$16.81
Day$15.50–17.30
52W$15.10–20.30
Avg vol 30d335K
Short int1.8M · 3.7% float · 3.7d
Short vol90%
DataMay 2026–Jul 2026
Filing10-Q · Jun 17
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jun 17, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
RSI (14)
47
neutral
MACD trend
Negative
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$75.3M over 90 days · 13% sells
Short interest
Rising
3.74% of float · ▲ +33.7% MoM · 3.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Squeeze score
63
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$75.3M over 90 days · 13% sells
Short interest
Rising
3.74% of float · ▲ +33.7% MoM · 3.7 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
52-wk low $15
Now $17 · 31%
52-wk high $20
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ODTX
this stock
Odyssey Therapeutics, Inc.
|
$754.09M | — | — | — | 3.7% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ODTX | -0.7% | +3.0% | — | -10.8% | — |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.0% | -1.1% | — | -11.9% | — |